IGF1 and sarcopenia: Subsequently, we found that reducing the expression of IGFBP5 partially alleviated fibrosis in sarcopenic muscle by moderately potentiating the effects of IGF-1, providing clue to the development of novel anti-fibrosis therapies in sarcopenia.